Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML Patients Ineligible for Standard Treatment – – Supplemental New Drug...
-
– 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in Ivosidenib-treated Patients with Secondary AML – – 77% CR+CRi/CRp Rate in Enasidenib-treated Patients with De Novo AML...
-
– Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining on Treatment Provides Evidence of Prolonged Disease Control – – Favorable Safety Profile at 10 mg...
-
– Updated Single Agent Ivosidenib Data in Previously Untreated Acute Myeloid Leukemia (AML) Patients from Phase 1 Study Chosen for Oral Presentation – – Updated Data from Phase 1 Frontline AML...
-
– Supplemental New Drug Application Submission for Single Agent TIBSOVO® (ivosidenib) in Newly Diagnosed IDH1m AML Patients Not Eligible for Standard Treatment Planned by the End of January 2019 – –...
-
CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
-
- David Schenkein, M.D., Agios Long-Time Chief Executive Officer, to Become Executive Chairman, Effective February 1, 2019 - - Jacqualyn Fouse, Ph.D., to Succeed Dr. Schenkein as Chief Executive...
-
CAMBRIDGE, Mass, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
-
– TIBSOVO® Launch Underway Post FDA Approval for IDH1m R/R AML; Second Medicine Approved from Agios’ Discovery Platform in 12 Months – – Entered License Agreement with CStone Pharmaceuticals to...
-
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...